Financial Highlights

Boehringer Ingelheim Group of companies

Boehringer Ingelheim again posted gratifying growth over the previous year in the first six months of 2009.
Get an overview of the Financial Results of the first half year 2009.
Boehringer Ingelheim Corporation 1st Half 2009 1st Half 2008 Change in % Currency-
Adjusted in %
Net sales 6,388 5,522 +16 % +8.3 %
Human Pharmaceutical Business
of which
6,102 5,306 +15 % +7.5 %
  Prescription Medicines 5,107 4,354 +17 % +9.1 %
  Consumer Healthcare 609 569 +7 % +1.0 %
  Industrial Customer* 382 382 +0 % -2.3 %
Animal Health Business 286 216 +32 % +27.9 %
Personnel Capacity** 39,944 39,819 +0.3 %
* incl. Biopharmaceuticals, Pharma Chemicals and Pharmaceuticals Production
** excl. Apprentices
Figures in EUR million or %
  2008 2007 Change
Net sales 11,595 10,952 +6 %
Net sales by region
Europe 33 % 33 %
Americas 48 % 50 %
Asia, Australasia, Africa 19 % 17 %
Net sales by business area
Human Pharmaceuticals 96 % 96 %
Animal Health 4 % 4 %
       
Research and Development 2,109 1,900 +11 %
Personnel costs 3,004 2,886 +4 %
Average number of employees 41,300 39,800 +4 %
Operating income 1,980 2,100 -6 %
Operating income as % of sales 17.1 % 19.2 %
Income after taxes 1,428 1,812 -21 %
Income after taxes as % of sales 12.3 % 16.5 %
Shareholders' equity 4,703 3,372 +39 %
Return on shareholders' equity 42.2 % 35.0 %
Cash Flow 1,997 2,392 -17 %
Investments in tangible assets 665 654 +2 %
Depreciation of tangible assets 453 432 +5 %
Amounts in millions of EUR, unless otherwise indicated